Form 8-K EAGLE PHARMACEUTICALS, For: Feb 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Eagle Pharmaceuticals (EGRX) to reduce current workforce by approximately 36%
February 29, 2024 8:14 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) disclosed:
On February 28, 2024, the Board of Directors of Eagle Pharmaceuticals, Inc. (the Company) approved a plan designed to improve operational efficiencies and realign the Companys sales and marketing expenditures (the Realignment Plan).
The Realignment Plan is expected to reduce the Companys current workforce by approximately 36%. Substantially all affected employees are currently dedicated to or primarily supporting the commercialization of Byfavo, Barhemsys and Ryanodex. The Company intends to utilize a reduced team dedicated to these products in addition to resources from the... More
